Clinical Trial

A Study of LAD106 in Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-30 -> 2027-05-31 2026-05-16
minor Completion pushed: 2026-06-30 -> 2027-05-31 2026-05-16
Trial Details
NCT Number NCT07471932
Lead Sponsor Almirall, S.A.
Conditions Healthy Volunteers
Enrollment 93 participants
Start Date 2026-02-17
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-15